What did UBS change in its LLY analyst rating on Feb 02, 2026?

UBS **maintained** its Buy rating on Eli Lilly (LLY) on February 02, 2026 at 09:59 AM and did not publish a new price target in the note per the StreetInsider report.

How should investors interpret a maintained Buy in the LLY analyst rating?

A maintained Buy signals continued analyst conviction without new catalyst. It supports holding or gradual accumulation for long-term investors and suggests limited immediate upside from the note alone.

Did the UBS note change the LLY price target?

No. UBS reiterated a Buy but did not issue a new LLY price target in the published comment, so there is no target update to act on from this note alone.

How does the LLY analyst rating tie into Meyka AI’s view?

Meyka AI rates LLY **B+**, factoring in benchmark comparison, sector placement, financial growth, and analyst consensus. The maintained Buy from UBS aligns with that constructive grading.

Analyst Ratings

UBS Maintains Buy on Eli Lilly (LLY) Feb 2026

ByHuzaifa Zahoor February 3, 2026

UBS maintained its Buy rating on Eli Lilly and Company (LLY) on February 02, 2026 at 09:59 AM, reiterating confidence after recent company moves. The LLY analyst rating note shows no change in stance and comes as the stock moved -0.9% (down $9.48) on the day. UBS did not publish a new price target in the note. This maintained Buy keeps Eli Lilly in many growth-focused analyst portfolios and matters for investors weighing exposure to large-cap biotech with a $935,085,102,650 market cap.